Stabilized severe osteoporosis: Should the treatment be stopped?

Joint Bone Spine

Volumn 77, Issue SUPPL. 2, 2010, Pages

  Paccou, Julien ^a   Confavreux, Cyrille B ^b   David, Claire ^c   Leboime, Ariane ^d   Mehsen, Nadia ^e   Cortet, Bernard ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE LYON   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔPITAL PELLEGRIN   (France)

Author keywords

Duration; Osteoporosis; Severity; Treatment

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE NECROSIS; BONE TURNOVER; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG WITHDRAWAL; FRACTURE; FRAGILITY FRACTURE; HIGH RISK POPULATION; HUMAN; JAW OSTEONECROSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); VERTEBRA FRACTURE;

EID: 78650750059     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1297-319X(10)70007-5     Document Type: Article

References (44)

1. Laroche M. Treatment of osteoporosis: All the Questions we still cannot answer. Am J Med 2008, 121(9):744-747.
2. Roux C. Selecting first-line treatment for patients with osteoporosis. Joint Bone Spine 2008, 75:257-259.
3. Fardellone P. Predicting the fracture risk in 2008. Joint Bone Spine 2008, 75:661-664.
4. Bliuc D., Nguyen N.D., Milch V.E., et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009, 301:513-521.
5. Recommandations de la HAS, 2006. Prévention, diagnostic, et traitement de l"ostéoporose.
6. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
7. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077-2082.
8. Liberman U.A., Weiss S.R., Bröll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995, 333:1437-1443.
9. Bone H.G., Hosking D.H., Devogelaer J.P., et al. Ten years" experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189-1199.
10. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 24:2927-2938. FLEX Research Group.
11. Cummings S., Shinoff C., Palermo L., et al. Effects of 10 years of alendronate on the risk of non-spine fracture. A novel approach to modeling long-term effects of treatments. Annual Congress of the American Society for Bone Mineral Research 2005, Abst. M365.
12. Harris S.T., Watts N.B., Genant H.K. Effects of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999, 282:1344-1352.
13. Reginster J.Y., Minne H.W., Sorensen O.H., et al. Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000, 11:83-91.
14. Mc Clung M.R., Geusens P., Miller P.D., et al. Hip intervention program study group: effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. N Engl J Med 2001, 344:333-340.
15. Sorensen O.H., Crawford G.M., Mulder H., et al. Long-term efficacy of risedronate: a 5-year placebo controlled clinical experience. Bone 2003, 32:120-126.
16. Mellstrom D., Sorensen O.H., Goemaere S., et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 75:462-468.
17. Delmas P.D., Recker R.R., Chesnut C.H., et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004, 10:792-798.
18. Black D.M., Delmas P.D., Eastell R., et al. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356(18):1809-1822.
19. Lyles K.W., Colón-Emeric C.S., Magaziner J.S., et al. HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
20. Meunier P.J., Roux C., Seeman E., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with post-menopausal osteoporosis. N Engl J Med 2004, 350:459-468.
21. Reginster J.Y., Seeman E., De Vernejoul M.C., et al. Strontium ranelate reduces the risk of non vertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005, 90:2816-2822.
22. Reginster J.Y., Felsenberg D., Boonen S., et al. Effects of long-term strontium ranelate treatment on the risk of non vertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008, 58:1687-1695.
23. Reginster J.Y., Bruyère O., Sawicki A., et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone 2009, 6:1059-1064.
24. Bruyère O., Roux C., Badurski J., et al. Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin 2007, 23:3041-3045.
25. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifène. Results from a 3-year randomized clinical trial. JAMA 1999, 282:637-645.
26. Delmas P.D., Ensrud K.E., Adachi J.D., et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002, 87:3609-3617.
27. Siris E.S., Harris S.T., Eastell R., et al. Cummings SR and For the Continuing Outcomes Relevant to Evista (CORE) Investigators. Skeletal effects of Raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res 2005, 20:1514-1524.
28. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
29. Harper K.D., Krege J.H., Marcus R., et al. Osteosarcoma and teriparatide?. J Bone Miner Res 2007, 22:334.
30. Curtis J.R., Westfall A.O., Cheng H., et al. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 2008, 19:1613-1620.
31. Watts N.B., Chines A., Olszynski W.P., et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008, 19:365-372.
32. Roux C. Strontium ranelate: short- and long-term benefits for post-menopausal women with osteoporosis. Rheumatology (Oxford) 2008, 47(Suppl 4):iv20-iv22.
33. Neele S.J., Evertz R., De Valk-De Roo G., et al. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002, 30:599-603.
34. Lindsay R., Scheele W.H., Neer R., et al. Sustained vertebral fracture risk reduction after withdrawal of tériparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004, 164:2024-2030.
35. Ruggiero S.L., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004, 62:527-534.
36. Vieillard M.H., Maes J.M., Penel G., et al. Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint Bone Spine 2008, 75(1):34-40.
37. Khosla S., Burr D., Cauley J., et al. American Society for Bone and Mineral Research. Bisphosphonate-associated Osteonecrosis of the jaw: Report of a task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479-1491.
38. Woo S.B., Hellstein J.W., Kalmar J.R., et al. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006, 144:753-761.
39. Biezikian J.P. Osteonecrosis of the jaw-do bisphosphonates pose a risk?. N Engl J Med 2006, 355:2278-2281.
40. Ott S.M. Fractures after long-term Alendronate therapy. JCEM 2001, 86:1835-1836.
41. Odvina C.V., Zerwekh J.E., Rao D.S., et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
42. Mashiba T., Turner C.H., Hirano T., et al. Effects of high-dose etidronate treatment on microdamage accumulation and biochemical properties in beagle bone before occurrence of spontaneous fractures. Bone 2001, 29:271-278.
43. Mashiba T., Turner C.H., Hirano T., et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biochemical properties in clinically relevant skeletal sites in beagles. Bone 2001, 28:524-531.
44. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24:1095-1102.